Provirus activation plus CD59 blockage triggers antibody-dependent complement-mediated lysis of latently HIV-1-infected cells by Lan, Jie et al.
Provirus activation plus CD59 blockage triggers antibody-
dependent complement-mediated lysis of latently HIV-1-infected
cells
Jie Lan*, Kai Yang*,#, Daniel Byrd*, Ningjie Hu#, Tohti Amet*, Nicole Shepherd*, Mona
Desai¶, Jimin Gao*, Samir Gupta¶, Yongtao Sun**, and Qigui Yu*,¶,§
*Department of Microbiology and Immunology and Center for AIDS Research, Indiana University
School of Medicine, 635 Barnhill Drive, Indianapolis, IN 46202
#Zhejiang Provincial Key Laboratory for Technology & Application of Model Organisms, Wenzhou
Medical College, University Park, Wenzhou 325035, China
¶Division of Infectious Diseases, Department of Medicine, Indiana University School of Medicine,
545 North Barnhill Drive, Indianapolis, IN46202-5124
**Department of Infectious Diseases, Tangdu Hospital, Fourth Military Medical University, Xi’an
710038, China
Abstract
Latently HIV-1-infected cells are recognized as the last barrier towards viral eradication and cure.
To purge these cells, we combined a provirus stimulant with a blocker of human CD59, a key
member of the regulators of complement activation (RCA), to trigger antibody-dependent
complement-mediated lysis (ADCML). Provirus stimulants including prostratin and histone
deacetylase inhibitors (HDACi) such as romidepsin (RMD) and suberoylanilide hydroxamic acid
(SAHA) activated proviruses in the latently HIV-1-infected T cell line ACH-2 as virion
production and viral protein expression on the cell surface were induced. RMD was the most
attractive provirus stimulant as it effectively activated proviruses at nanomolar concentrations that
can be achieved clinically. Antiretroviral drugs including two protease inhibitors (atazanavir and
darunavir) and a reverse transcriptase inhibitor (emtricitabine) did not affect the activity of
provirus stimulants in the activation of proviruses. However, saquinavir (a protease inhibitor)
markedly suppressed virus production, although did not affect the percentage of cells expressing
viral Env on the cell surface. Provirus-activated ACH-2 cells expressed HIV-1 Env that
colocalized with CD59 in lipid rafts on the cell surface, facilitating direct interaction between
them. Blockage of CD59 rendered provirus-activated ACH-2 cells and primary human CD4+ T
cells that were latently infected with HIV-1 sensitive to ADCML by anti-HIV-1 polyclonal
antibodies or plasma from HIV-1-infected patients. Therefore, a combination of provirus
stimulants with RCA blockers represents a novel approach to eliminate HIV-1.
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Introduction
The eradication of human immunodeficiency virus type 1 (HIV-1) from infected individuals
remains a major medical challenge. Antiretroviral therapy (ART) has led to a profound
reduction in HIV-1-related morbidity and mortality. However, ART fails to eliminate the
virus in vivo. Most HIV-1-infected patients on ART still have residual viremia measurable
by ultrasensitive assays, and many of them also experience transient episodes of viremia
(termed viral blips) above the detection limit of standard diagnostic assays (1–3). The
persistent viremia mainly arises from replication-competent proviruses in long-lived latently
infected cells, which represent a major obstacle for HIV-1 eradication (4–8).
Efforts to purge long-lived latently infected cells have focused on activation of the
proviruses in these cells. It is presumed that these infected cells will be killed after activation
of virus gene expression by viral cytopathic effects (CPEs), host immune responses or both.
This has been known as the “shock and kill” approach (9, 10). Several stimulants including
IL-7, prostratin, and histone deacetylase inhibitors (HDACi) such as valproic acid (VPA)
and suberoylanilide hydroxamic acid (SAHA or Vorinostat) have been explored to force
activation of proviruses in latently-infected resting CD4+ T cells that constitute the major
reservoir of HIV-1 in vivo. However, treatment with IL-7, VPA or SAHA in patients on
ART has failed to reduce HIV-1 latency (11–14), suggesting that these stimulants alone are
not sufficient to induce killing of latently infected cells. The underlying mechanisms of the
failure to induce cell killing are unclear, but may include: (1) HIV-1 replication elicits little
CPEs in vivo (15–19), (2) impaired host immunity in chronically HIV-1-infected patients is
not fully restored with ART (20–24), and (3) these stimulants are not potent enough to fully
activate proviruses in latently infected cells, and the cells can then survive long enough to
revert back to a resting memory state if they are not killed (7, 25). A recent study has
demonstrated that cytolytic T lymphocytes (CTLs) from HIV-1-infected patients on ART
require extra antigen-specific stimulations in order to kill latently-infected CD4+ T cells
after provirus activation (26). Therefore, there is an urgent need to improve this “shock and
kill” approach by identifying more potent proviral stimulants in conjunction with agents that
enable anti-HIV-1 immunity to specifically kill latently infected cells after provirus
activation.
Both HIV-1-infected cells and virions use their surface regulators of complement activation
(RCA) to resist antibody-dependent complement-mediated lysis (ADCML) (27–31). In
HIV-1-infected patients, the virus-specific antibody (Ab) response is vigorous at all stages
of infection. Within a few weeks of infection, Abs against the viral envelope (Env or gp120
plus gp41), core (Gag), and matrix (p17) become detectable in the plasma of HIV-1-positive
individuals (32–37). Ab levels mount in response to the gradual increase in viral load and
appear to be maintained at high levels throughout the disease (38, 39). However, the
vigorous and sustained Ab response has a limited effect on controlling virus proliferation or
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on protecting the patients from developing AIDS (38, 40–42). Recent studies have
demonstrated that Abs present in the circulation of HIV-1-infected patients are able to
specifically recognize and bind both autologous and heterologous primary HIV-1 isolates
(43), but fail to complete ADCML against virions and infected cells due to the presence of
RCA in the HIV-1 Env or on the membrane of the infected cells (27–29). Abrogation of the
biological function of RCA members, particularly CD59 (a key RCA member that controls
formation of the membrane attack complex at the terminal stage of the complement
activation cascades via all three activation pathways), has rendered both HIV-1-infected
cells and virions sensitive to ADCML (27–31, 44). Thus, a combination of provirus
stimulants and RCA blockers would allow anti-HIV-1 Abs naturally present in HIV-1-
infected individuals to trigger ADCML of latently infected T cells upon provirus activation.
This would represent a novel approach to promote specific killing of latently HIV-1-infected
cells towards an HIV-1 cure.
Using ACH-2 cells (a human T cell line latently infected with HIV-1LAV strain) as an in
vitro latency model, we evaluated the biological effects of prostratin and HDACi including
romedepsin (RMD) and SAHA on provirus activation. We then evaluated ADCML efficacy
of provirus-activated cells that were latently infected with HIV-1 in the presence of a
blocker of human CD59 (hCD59) plus anti-HIV-1 Abs or plasma from HIV-1-infected
patients who were on ART or ART-naïve. Our data demonstrated that prostratin and
HDACi, particularly RMD, activated provirus to induce both virion production and viral
protein expression on the cell surface. Blockage of CD59 rendered provirus-activated cells
that were latently infected with HIV-1 including ACH-2 cells and primary human CD4+ T
cells sensitive to ADCML by anti-HIV-1 Abs or plasma from HIV-1-infected patients.
Materials and Methods
Blood samples from HIV-1-infected and uninfected donors
Peripheral blood was collected in BD Vacutainer tubes (containing 158 USP units of sodium
heparin per 10-ml tube, BD, Franklin Lakes, NJ) from 6 ART-naïve HIV-1-infected
patients, 9 virologically suppressed HIV-1-infected patients on ART with viral RNA less
than 50 copies/ml of plasma for 6 months or more (Table 1), and 5 HIV-1-negative (healthy)
blood donors. Plasma was separated from blood cells by centrifugation and then stored at
-80°C until use. Blood cells were subjected to isolation of red blood cells (RBCs) and
peripheral blood mononuclear cells (PBMCs) using the Ficoll-Hypaque density gradient
centrifugation (Amersham Pharmacia Biotech AB, Uppsala, Sweden). Fresh RBCs isolated
from healthy blood donors were subjected to a hemolytic assay to determine biological
activity of complement in plasma from HIV-1-infected patients and the optimal
concentration of BRIC229, a mouse monoclonal Ab (mAb) widely used to block hCD59
without activating complement activity (IBGRL, Bristol, UK), for abrogation of hCD59
function (45). Written informed consent was provided by each participant. All
investigational protocols were approved by the Indiana University Institutional Review
Board (Indianapolis, IN).
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Hemolytic assay
Fresh RBCs isolated from healthy blood donors were washed four times with phosphate
buffered saline (PBS), and then were used for a hemolytic assay as previously described
(44). Briefly, RBCs (5,000 cells) were incubated with BRIC229 at various concentrations
ranging from 1–20 μg/ml at 37°C for 30 min to abrogate hCD59 function. Cells were then
incubated with rabbit anti-human RBCs polyclonal Abs (pAbs, MyBioSource, San Diego,
CA) plus serially diluted plasma from HIV-1-infected patients or healthy blood donors.
Every experiment included heat-inactivated plasma as a control of complement inactivation
to obtain background hemolysis, while total hemolysis was obtained by adding pure water to
the RBCs pellet. All experiments were carried out in triplicates. The amount of hemoglobin
released from lysed RBCs was determined by the optical density (OD) of the supernatant at
414 nm, and the percent lysis was calculated as follows: (experimental OD414 − background
OD414)/(total lysis OD414 − background OD414)×100.
Latently HIV-1-infected cells and provirus activation
J-Lat GFP Clone A72, ACH-2 and A3.01 cells were obtained through the NIH AIDS
Reagent Program (Germantown, MD). The J-Lat GFP Clone A72 cell line contains
integrated but transcriptionally latent HIV-1 proviruses. The cell line was generated by
transduction of Jurkat cells with the HIV-1-based vector consisting of Tat and enhanced
green fluorescent protein (GFP) under the control of the HIV-1 LTR (5′-LTR-Tat-IRES-
GFP-LTR-3′) (46, 47). J-Lat GFP Clone A72 cells are GFP-negative under basal conditions
and become GFP-positive after activation of HIV-1 latency (46, 47). ACH-2 is a human T
cell line latently infected with HIV-1LAV strain, while A3.01 is the parental uninfected cell
line. Cells were grown in the complete RPMI 1640 medium (RPMI 1640 medium
supplemented with 10% FBS, 5% penicillin-streptomycin, and 2 mM glutamine). Cells were
untreated or treated for 24 - 72 h with RMD, SAHA, or prostratin at various concentrations
in the presence or absence of antiretroviral drugs at various concentrations. Reverse
transcriptase (RT) inhibitor such as emtricitabine (FTC, Selleckchem, Houston, TX) or
protease inhibitor (PIs) such as saquinavir (SQV, Tocris, Bristol, UK), atazanavir (ATV,
ApexBio, Houston, TX) or darunavir (DRV, ApexBio, Houston, TX) was used. These
stimulants were purchased from Sigma-Aldrich (St. Louis, MO). Phorbol myristyl acetate
(PMA at 10 ng/ml; Sigma, St. Louis, MO) plus ionomycin (1 μg/ml; Sigma, St. Louis, MO)
and DMSO were used as positive and negative stimulation controls, respectively. Stimulated
J-Lat GFP Clone A72 cells were directly subjected to fluorescence microscopy analysis
using Evo FL Auto Cell Imaging System (Life Technologies, Grand Island, NY). Stimulated
ACH-2 cells or A3.01 cells were subjected to immunostaining to determine expression of
HIV-1 Env on the cell surface, while the supernatant was subjected to measurement of
HIV-1 p24 using the p24 Antigen ELISA kit (PerkinElmer, Santa Clara, CA) to determine
levels of HIV-1 production in response to various provirus stimulants.
ADCML of ACH-2 cells by anti-HIV-1 Env pAbs
Antibody-dependent complement-mediated lysis (ADCML) of latently HIV-1-infected
ACH-2 cells was quantified using the calcein release assay. Briefly, ACH-2 or A3.01 cells
untreated or treated with RMD, PMA/ionomycin, or DMSO in the presence or absence of
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antiretroviral drugs were labeled at 37°C for 40 min with 15 μM calcein-AM dye
(Invitrogen, Carlsbad, CA) in 200 μl of PBS. The cells were washed three times with PBS to
remove the free calcein-AM dye, and resuspended in the complete RPMI 1640 medium at a
concentration of 1 × 106 cells per ml. Cells were dispensed into round-bottom 96-well
microplates (100 μl containing 10,000 cells per well). Cells were pre-incubated for 30 min at
37°C with or without BRIC229 (20 μg/ml) in the presence of anti-gp120/gp160 pAbs at
various concentrations (Abcam, Cambridge, MA). After the pre-incubation, 50 μl of the
pooled sera from three healthy blood donors were added as a source of complement. The
microplates were incubated at 37°C for 1 h, and followed by centrifugation at 130 g for 5
min. After the centrifugation, 100 μl of supernatant from each well was transferred into fresh
96-well microplates for measuring the fluorescence intensity using an automated
fluorescence plate reader (Molecular Devices, Sunnyvale, CA). To measure maximum
fluorescence intensity, a sample of calcein-labeled cells was lysed with 200 μl of Triton
X-100 (5% in PBS). To obtain baseline or spontaneous cytolysis data, parallel ADCML
assays were run with heat-inactivated sera from these healthy blood donors, culture medium
alone, or irrelevant pAbs. All experiments were carried out in triplicates. The percent
cytolysis of ADCML was determined as follows: % cytolysis = (experimental cytolysis -
spontaneous cytolysis)/(maximum cytolysis - spontaneous cytolysis) X 100.
ADCML of ACH-2 cells by anti-HIV-1 Abs in plasma of HIV-1-infected patients
The calcein release assay was also used to quantitate ADCML of latently HIV-1-infected
ACH-2 cells by anti-HIV-1 Abs in plasma samples from HIV-1-infected patients. ACH-2 or
A3.01 cells untreated or treated with RMD, PMA/ionomycin, or DMSO were labeled at
37°C for 40 min with 15 μM calcein-AM (Invitrogen, Carlsbad, CA) in 200 μl of PBS. After
washing, cells were pre-incubated for 30 min at 37°C with BRIC229 (20 μg/ml) to block
hCD59 function. After pre-incubation, heat-inactivated plasma (56°C for 1 h) from either
HIV-1-infected or healthy individuals (1:20 at final dilution) were individually added as a
source of endogenous Abs or Ab control, followed by the exposure to either complement-
competent or heat-inactivated sera from healthy blood donors. Triton X-100 was used for
determining the total cytolysis. All experiments were carried out in triplicates and percent
cytolysis was calculated as described above.
Establishment of HIV-1 latency in primary resting CD4+ T cells
Establishment of HIV-1 latency in primary resting CD4+ T cells was conducted using the
spinoculation-infection approach as previously described (48). Briefly, leukapheresis
products from 3 HIV-1-negative blood donors were purchased from the ALLCells
(Emeryville, CA) for isolation of primary CD4+ T cells using the negative selection
RosetteSep reagents (StemCell Technologies, Vancouver, BC, Canada). The isolated CD4+
T cells were stained with Abs against the human T cell activation markers of CD69, HLA-
DR and CD25, and followed by fluorescence-activated cell sorting (FACS) to obtain resting
CD4+ T cells that were activation marker negative as previously described (48). The purity
of primary resting CD4+ T cells was >97% by FACS analysis. The primary resting CD4+ T
cells were subjected to spinoculation-infection of HIV-1 as previously described (48).
Primary resting CD4+ T cells at 0.2 - 1.0 × 106 per well in flat-bottom 96-well microplates
were mixed with HIV-1 strain of NL4-3 (NIH AIDS Reagent Program, Germantown, MD)
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at 0.5 – 3.0 μg/ml of p24Gag. The microplates were enclosed in plastic bags and centrifuged
in microtiter plate carriers at 1,200 x g for 2 h at room temperature. The cells were washed
five times with ice-cold RPMI 1640 medium to remove free HIV-1 particles, followed by
resuspension in the complete RPMI1640 medium supplemented with 5 μM saquinavir
(SQV, a protease inhibitor or PI; Sigma-Aldrich, St. Louis, MO) to prevent infection by
residual virus. The cells and supernatants were harvested immediately after spinoculation-
infection and at multiple time points of culture for evaluation of HIV-1 latency. Cells were
subjected to DNA extraction using the DNeasy Blood & Tissue Kit (Qiagen, Valencia, CA)
for determination of integrated HIV-1 DNA by the nested Alu-Gag qPCR assay, while the
culture supernatants were subjected to p24 ELISA for measurement of virus production as
described above. In principle, latently-infected resting CD4+ T cells have high levels of
integrated HIV-1 DNA in cells, but low or undetectable levels of viral p24 in culture
supernatants.
The nested Alu-Gag qPCR assay to quantify integrated HIV-1 DNA
DNA extracted from latently-infected primary resting CD4+ T cells was subjected to the
nested Alu-Gag qPCR assay to quantify integrated HIV-1 DNA as previously described (49).
The nested Alu-Gag qPCR assay used two sequential sets of primers. The first set of primers
was: genomic Alu forward, 5′-GCCTCCCAAAGTGCTGGGATTACAG-3′; and HIV-1 Gag
reverse, 5′-GCTCTCGCACCCATCTCTCTCC-3′ (49). This primer set was used for the
first-round of PCR in the reaction conditions: 100 ng of extracted DNA, 1X Taq PCR
Master Mix (QIAGEN, Valencia, CA), 100 nM Alu forward primer, and 600 nM Gag
reverse primer. PCR cycling conditions were: a 120-sec hot start at 94°C, followed by 20
cycles of 93°C for 30 sec, 50°C for 60 sec, and 70°C for 100 sec. The first-round PCR
products (12.5 μl) were subjected to qPCR containing the second set of primers (LTR
forward, 5′-GCCTCAATAAAGCTTGCCTTGA-3′; and LTR reverse, 5′-
TCCACACTGACTAAAAGGGTCTGA-3′), each at 250 nM plus 1X RT2 SYBR Green
Rox qPCR Mastermixs (QIAGEN, Valencia, CA). The reactions were performed on a Prism
7700 Sequence Detection System running Sequence Detector version 1.6.3 software
(Applied Biosystems, Foster City, CA). The thermal program was 120-sec hot start at 95°C,
followed by 40 cycles of 95°C for 15 s and 60°C for 60 sec.
Plasmid pNL4-3 construct containing full-length of HIV-1 DNA was used to establish a
standard curve in the qPCR performance for quantitative analysis of integrated HIV-1 DNA
copy numbers. Plasmid pNL4-3 concentration was determined using a ND-1000 UV–vis
Spectrophotometer (NanoDrop Technologies, Wilmington, DE). The number of pNL4-3
copies in the plasmid solution was calculated according to the plasmid size of 14,825 bp. A
plasmid-based calibration curve was generated with 10-fold serial dilutions of pNL4-3; to
control pipetting steps, three 10-fold serial dilutions were prepared, and concentrations were
checked by qPCR. The quantification was linear over a range of 10 to 107 starting plasmid
copy numbers, and the detection limit was ten copies per reaction. The human β-globin gene
was used as an internal control for the normalization of the amount of viral DNA in each
sample. In addition, DNA samples prepared from ACH-2 and A3.01 cells were used as
positive and negative controls of HIV-1 DNA integration, respectively. The nested Alu-Gag
qPCR detects only integrated proviruses because it relies on an initial amplification in which
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one primer hybridizes with HIV-1 Gag sequence, while the other primer hybridizes with a
conserved sequence in Alu elements that are most numerous repetitive elements in primate
genomic DNA (49).
ADCML of latently HIV-1-infected primary resting CD4+ T cells by anti-HIV-1 Env pAbs
Spinoculation-infection approach can establish HIV-1 latency in approximately 4.5% of
primary resting CD4+ T cells that produce virus upon stimulation (48). The calcein release
assay described above is not sensitive enough to determine ADCML efficacy of such a small
percentage of latently HIV-1-infected primary resting CD4+ T cells. We then used the
nested Alu-Gag qPCR to measure the reduction of integrated HIV-1 DNA to indirectly
determine ADCML efficacy of latently infected primary CD4+ T cells. Briefly, latently
infected primary CD4+ T cells were untreated or treated with RMD, PMA/ionomycin, or
DMSO for 24 h at 37°C. Cells were pre-incubated for 30 min at 37°C with or without
BRIC229 (20 μg/ml) in the presence of anti-gp120/gp160 pAbs at various concentrations
(Fitzgerald, Acton, MA). After the pre-incubation, 100 μl of the pooled sera from three
healthy blood donors were added as a source of complement. Parallel tests were run with
heat-inactivated sera from these healthy blood donors to obtain spontaneous cytolysis data.
The microplates were incubated at 37°C for 1 h and followed by 3 washes with ice-cold
PBS. Cells in all ADCML experimental conditions described above were treated with
DNase enzymes to remove DNA released from lysed cells, and then subjected to DNA
extraction for quantitating integrated HIV-1 DNA using the nested Alu-Gag qPCR as
described above (49). ADCML efficacy of latently HIV-1-infected primary resting CD4+ T
cells by anti-HIV-1 Env pAbs was calculated as fold reductions of integrated HIV-1 DNA
copies detected in ADCML experimental conditions (anti-gp120/gp160 pAbs plus
competent complement or heat-inactivated complement) versus that detected in the ADCML
control (anti-gp120/gp160 pAbs only).
Titration of plasma anti-HIV-1 Env Abs from HIV-1-infected patients
Anti-HIV-1 Env Abs in plasma samples from infected patients on ART or ART-naïve were
titrated using an ELISA Kit for Antibody to Human Immunodeficiency Virus 1&2
(BioChain, Hayward, CA). The 96-well microplates included in this kit were coated with the
recombinant HIV antigens (gp120, gp36, and gp47), which specifically capture anti-HIV
Env Abs. Test results for HIV-2 specific Abs, as measured by the FDA-licensed HIV-2
enzyme immunoassay, were negative in all subjects. Therefore, Abs measured by this
ELISA kit were specifically against HIV-1 Env.
Each plasma sample was serially diluted fourfold starting from 1:800 in the Blocker Casein
Buffer (Thermo Scientific, Rockford, IL). Each dilution (100 μl) was added to a well and
incubated at 37 °C for 1 h. Five HIV-1-negative plasma samples were diluted in the same
pattern and added as negative controls. After washing, 100 μl of 1:50000-diluted horseradish
peroxidase (HRP)-conjugated anti-human whole IgG mAb (Millipore, Temecula, CA) was
added per well and incubated at 37 °C for 1 h. Microplates were washed and substrate was
added, followed by incubation at room temperature in darkness for 20 min. The reaction was
stopped by 2 M sulfuric acid and the optical density of each well was read at 450 nm. All
diluted samples were tested in duplicate. The cut-off was determined as the mean
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absorbance value of five plasma samples from HIV-1-negative donors. The Ab titer was
determined as the highest dilution with an absorbance value above the cut-off.
Flow cytometric analysis (FACS)
ACH-2 or A3.01 cells were stimulated with RMD (1 - 9 nM), SAHA (0.2 - 0.8 μM), or
prostratin (0.2 - 5 μM) for 24 - 72 h. PMA (10 ng/ml)/ionomycin (1 μg/ml) and DMSO were
included as positive and negative stimulation controls, respectively. Cells were subjected to
surface staining with 2G12, an anti-HIV-1 gp120 mAb, to determine expression of HIV-1
Env on the cell surface. The percentage of latently infected primary resting CD4+ T cells
that produced virus upon stimulation was determined by intracellular staining (ICS) for
HIV-1 Gag. The BD Cytofix/Cytoperm Plus Kit (BD Biosciences, San Diego, CA) was used
for the ICS in accordance with the manufacturer’s recommendations. Cells were stained
with phycoerythrin-labeled KC57 (Beckman Coulter, Fullerton, CA) mAb. This IgG1 mAb
recognizes p55, p39, p33, and p24 proteins of the core antigens of HIV-1.
FACS data of both cell surface staining and ICS were analyzed using FlowJo software (Tree
Star, San Carlos, CA).
Confocal microscopy
ACH-2 cells were treated with RMD (3 nM), SAHA (0.8 μM), or prostratin (1 μM) for 24 h.
PMA (10 ng/ml)/ionomycin (1 μg/ml) and DMSO were included as positive and negative
stimulation controls, respectively. Cells were fixed with 2% paraformaldehyde (PFA), and
then subjected to immunostaining for confocal microscopy analysis of viral protein
expression and colocalization of HIV-1 Env with CD59 and ganglioside M1 (GM1) lipid
rafts on the cell surface. Cells were incubated with cholera toxin subunit B (CTB)
conjugated with Alexa Fluor 488 (Life Technologies, Carlsbad, CA) at 4°C for 20 min to
stain GM1 lipid rafts as previously described (50). Anti-HIV-1 gp120 mAb cloned from an
HIV-1-positive individual (2G12, NIH AIDS Reagent Program, Germantown, MD) and
BRIC229 were used as primary Abs to stain Env and CD59, respectively. After washing,
cells were stained with the secondary Abs including goat anti-human IgG conjugated with
Alexa Fluor 633 and donkey anti-mouse IgG conjugated with Alexa Fluor 546. Both
primary- and secondary-Ab incubations were carried out for 30 min at room temperature
with 2% FBS/PBS. After staining, cells were adhered to poly-L-lysine-coated coverslips and
mounted onto glass slides using the ProLong Gold Antifade reagent (Life Technologies,
Carlsbad, CA) containing 4′,6-diamidino-2-phenylindole (DAPI) dye for fluorescent
staining of DNA content and nuclei. Cells were analyzed using an Olympus FV1000-MPE
confocal/multiphoton microscope fitted with a 60 objective lens. Images were processed and
analyzed using the FV10-ASW 3.0 Viewer software (Olympus America Inc., Center Valley,
PA).
Western blot
ACH-2 cells untreated or treated with RMD (3 nM), SAHA (0.8 μM), prostratin (1 μM),
PMA (10 ng/ml)/ionomycin (1 μg/ml) or DMSO in the presence or absence of antiretroviral
drugs for 24 h were lysed in 1 X cell lysis buffer (Cell Signaling Technology, Danvers, MA)
plus 1 X Protease Inhibitor Cocktail (Sigma-Aldrich, St. Louis, MO). Cellular lysates were
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cleared by centrifugation at 13,800 x g for 15 min at 4 °C, and then subjected to NuPAGE
Novex high-performance electrophoresis (Invitrogen, Carlsbad, CA). Proteins were blotted
onto a polyvinylidene difluoride (PVDF) membrane (Millipore, Billerica, MA). After
blocking with 5% of non-fat milk, the blot was incubated overnight at 4°C with mouse anti-
Gag pAbs at 1 μg/ml. After washing, the blot was visualized with the appropriate HRP-
conjugated secondary Ab and an enhanced chemiluminescence (ECL) detection system
(Pierce, Rockford, IL). To ensure that equal amounts of cellular proteins were analyzed, the
same blot was used for the detection of human β-actin protein expression after stripping,
blocking, and incubation with mouse anti-human β-actin protein mAb (Abcam, Cambridge,
MA) followed by incubation with HRP-conjugated anti-mouse IgG (Jackson Immuno-
Research Laboratories, West Grove, PA) and ECL detection system.
Statistical analysis
Data were compared using Tukey’s Post hoc ANOVA test or the Student t-test. p < 0.05 was
considered statistically significant.
Results
Expression of viral Env on the surface of latently HIV-1-infected cells upon provirus
activation
Several reagents including prostratin and HADCi such as VPA and SAHA have been
explored to force activation of provirus in latently HIV-1-infected cells in vivo and in vitro
(14, 51–54). These reagents are able to activate provirus in latently HIV-1-infected primary
cells and cell lines, inducing viral transcription, increasing viral RNA expression, or
enhancing the acetylation of cellular histones (14, 51–54). It remains unclear whether and to
what extent these reagents induce expression of HIV-1 proteins on the surface of latently-
infected cells, which is critical for clearance of infected cells by immune responses. To
clarify these issues, we used J-Lat GFP Clone A72 cells to determine the optimal
concentrations of these reagents in provirus activation. We also included RMD in our
experiments as it is a novel selective and potent HDACi recently approved by FDA for
treatment of cutaneous T-cell lymphoma (CTCL). We found that all these reagents activated
proviruses in J-Lat GFP Clone A72 cells in a dose-dependent manner (Fig. 1A). RMD, at
nanomolar concentrations (3 nM or higher), effectively activated proviruses as GFP
expression was greatly induced, whereas SAHA and prostration were required at
micromolar concentrations to trigger GFP expression (Fig. 1A). We then used ACH-2 cells
to confirm the results described above and to study the effects of these reagents on HIV-1
protein expression on the cell surface. While Env-positive cells were barely detectable in
medium or DMSO treatment, RMD, SAHA and prostratin triggered expression of HIV-1
Env on the surface of ACH-2 cells in a dose-dependent manner (Fig. 1B, 1C). RMD at a
concentration as low as 3 nM strongly induced HIV-1 Env expression, as 54.4 ± 6.1% of
ACH-2 cells became gp120-positive 24 h post-stimulation. When RMD was used at 9 nM,
88.9 ± 7.5% of ACH-2 cells became gp120-positive 24 h post-stimulation. In contrast,
approximately 1 μM of prostratin was required to induce a level of Env expression similar to
that by RMD at 9 nM (Fig. 1B, 1C), and SAHA only induced a moderate level of Env
expression even at 0.8 μM or higher concentrations (Fig. 1B, 1C). It is pertinent to note that
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prostratin is a phorbol ester that antagonizes HIV-1 latency by activating NF-κB (55), which
may cause global cell activation leading to unacceptable side effects. Interestingly, the
percentage of Env-positive cells was not correlated with levels of viral particles released into
the culture supernatants (Fig. 1D). HIV-1 p24 in the supernatant of RMD-treated ACH-2
cells was almost 10-fold and 4-fold higher than that of SAHA- or prostratin-treated cells,
respectively (Fig. 1D). The smaller fold increase seen in the prostratin-treated cells may be
due to prostratin’s anti-HIV-1 activity (56, 57). The highest doses of RMD (9.0 nM,
equivalent to 1.62 mg/m2 in vivo) and SAHA (0.8 μM) in our experiments are within the
tolerated doses of these drugs used in CTCL patients. RMD is used to treat CTCL patients at
7–14 mg/m2 via intravenous infusion over a 4 h period (58), whereas SAHA is used at 400
mg once daily via oral administration (plasma concentration up to 400 – 600 ng/ml or 1.5 –
2.3 μM) (59). Thus, prostratin and HDACi, particularly RMD, are able to activate provirus
to induce both virion production and viral protein expression on the cell surface, which are
expected to trigger viral CPEs, immune responses, or both to kill provirus-activated cells.
Effects of ART on virus production and viral protein expression
The “shock and kill” approach has to be implemented in HIV-1-infected patients on ART to
prevent new rounds of infections by virus released from the stimulated cells. It is unclear
whether ART drugs interrupt the effects of provirus stimulants on virion production and
viral protein expression, thereby attenuating the effects of these provirus stimulants on
provirus activation. To clarify these issues, we treated ACH-2 cells with RMD (3 nM),
SAHA (0.8 μM), prostratin (1 μM), PMA (10 ng/ml)/iononycin (1 μg/ml), or DMSO in the
presence or absence of reverse transcriptase (RT) inhibitors or PIs as they are among the
most effective antiretroviral drugs. Supernatant and cells were then subjected to analysis of
virion production and expression of viral Env on the cell surface, respectively. We found
that emtricitabine (FTC, a RT inhibitor), atazanavir (ATV, a PI), and darunavir (DRV, a PI)
had no effect on provirus activation by provirus stimulants, as virus production in the
supernatants and percentage of Env-positive cells were not altered (Fig. 2A, 2B). Similar to
ATV and DRV, saquinavir (SQV, a PI) did not impact the effects of provirus stimulants on
expression of viral proteins on the cell surface, as percentage of Env-positive cells was not
dramatically changed (Fig. 2B). However, SQV markedly attenuated the effects of provirus
stimulants on virion production, as virions determined by p24 ELISA in the supernatant
released from ACH-2 cells in response to every stimulation condition markedly decreased
(Fig. 2A). Given that different PIs affect distinct steps in the viral life cycle, SQV probably
inhibits multiple steps of HIV-1 replication, resulting in the formation of defective particles
which contain precursor Gag (Pr55Gag) and little or no processed p24 (60). In fact, our
western blot analysis supports this notion because it demonstrates that Gag p41 and p24
were significantly reduced by SQV, but not ATV or DRV (Fig. 2C). In contrast, the levels
of Gag precursors (Pr55Gag) were comparable in the presence or absence of PIs (Fig. 2C).
Both RT and PI are key components of common ART regimens. They inhibit distinct steps
in the HIV-1 life cycle, resulting in the production of defective, noninfectious virions or
reduction of viral products. As a consequence, ART drugs, particularly PIs, may attenuate
the effects of provirus stimulants on viral CPEs in HIV-1-infected patients. Thus, the “shock
and kill” approach for purging latently HIV-1-infected cells should rely on immune
responses rather than viral CPEs.
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Colocalization of Env and hCD59 in lipid rafts on the surface of latently infected cells upon
provirus activation
Productively HIV-1-infected cells use their surface RCA molecules, mainly CD59, to resist
ADCML allowing them to escape the vigorous and sustained anti-HIV-1 Ab responses
observed in almost all infected individuals (28). This suggests CD59 is located in close
proximity to viral proteins such as Env on the cell surface, facilitating direct interaction
between them. We used a confocal microscopy assay to analyze CD59 and Env
colocalization on the surface of provirus-activated latently infected cells. The confocal
microscopy analysis confirmed our FACS data that RMD, SAHA, and prostratin triggered
provirus activation leading to Env expression on the cell surface (Fig. 3, gp120 panel). It is
well known that Env on the surface of productively infected cells is made of a trimer
consisting of three gp120/gp41 and that this trimeric Env is strongly associated with lipid
rafts (61–63). We found a similar association between Env and lipid rafts on the surface of
provirus-activated cells. We observed a multi-clustered Env distribution on the surface of
provirus-activated cells (Fig. 3, gp120 panel), which was exclusively colocalized with cell
membrane lipid rafts (Fig. 3, CTB panel). Importantly, CD59 was also strongly associated
with cell membrane lipid rafts (Fig. 3, CD59 panel), and Env and CD59 were colocalized in
lipid rafts on the surface of provirus-activated cells (Fig. 3, white in merge panel),
suggesting that Env may directly interact with RCA molecules on the cell surface. There
were no appreciable differences in the appearances of Env on the cell surface triggered by
different stimulants including PMA/ionomycin, RMD, SAHA, and prostratin (Fig. 3),
suggesting that expression of HIV-1 proteins on the cell surface can be triggered by different
provirus stimulants through distinct signaling pathways.
Anti-Env Abs-triggered ADCML of ACH-2 cells upon provirus activation
Next, we tested whether abrogation of CD59 function would render provirus-activated
ACH-2 cells sensitive to ADCML. Initial experiments using a hemolysis assay were
conducted to determine the most efficient blocking concentration of BRIC229 in abrogation
of hCD59 function. We found that BRIC229 at 20 μg/ml completely abrogated hCD59
function as ADCML of RBCs reached almost 100%, whereas RBCs were resistant to
ADCML in the absence of BRIC229 (Fig. 4A). We then used this concentration of BRIC229
(20 μg/ml) to block hCD59 on the surface of provirus-activated cells to analyze the ADCML
of latently HIV-1-infected cells. ACH-2 cells were stimulated with RMD (3 nM) in the
presence or absence of antiretroviral drugs such as FTC, SQV, ATV, or DRV. Cells were
treated with BRIC229 (20 μg/ml) plus purified rabbit anti-Env pAbs at various
concentrations and complement. Cytolysis of ACH-2 cells was measured by the calcein
release assay. We found that blockage of hCD59 with BRIC229 markedly increased
cytolysis of ACH-2 cells after provirus activation by RMD (Fig. 4B). Anti-Env pAbs
triggered cytolysis of provirus-activated ACH-2 cells in a dose-dependent manner (Fig. 4B).
The lysis resulted from specific cell killing by anti-HIV-1 Env pAb-mediated ADCML
because the lysis did not occur in the controls including: (1) no BRIC229, (2) irrelevant
rabbit IgG pAbs in place of anti-HIV-1 Env pAbs, (3) heat-inactivated complement, (4)
ACH-2 cells treated with DMSO, and (5) A3.01 cells that are ACH-2 parental cells prior to
HIV-1-infection (Fig. 4C). Cytolysis was not affected by antiretroviral drugs as cytolysis
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efficacy was not significantly altered in all experimental conditions in the presence or
absence of antiretroviral drugs (Fig. 4D).
ADCML of latently HIV-1-infected cells by plasma from HIV-1-infected patients
To evaluate whether provirus activation plus abrogation of hCD59 function renders latently
infected cells sensitive to ADCML by naturally occurring Abs present in the circulation of
HIV-1-infected patients, plasma samples from 15 chronically HIV-1-infected patients
including 9 patients who are on virally-suppressive ART (R01 – R09) and 6 ART-naïve
patients (G022, G023, G025, G026, G031, G040) (Table 1) were tested using the ADCML
assay described above. All plasma samples contained high titers of Abs against HIV-1 Env
(Table 1). Plasma samples from 5 HIV-1-negative blood donors were included as a cytolysis
control. Summary data of cytolysis of provirus-activated ACH-2 cells from all 15 HIV-1-
infected and 5 uninfected individuals are shown in Fig. 5A. In the presence of BRIC229, all
15 HIV-1 plasma samples contained Abs capable of mediating ADCML of provirus-
activated ACH-2 cells although in varying degrees (Fig. 5A), whereas plasma samples from
uninfected individuals did not produce significant ADCML. Specific ADCML of provirus-
activated ACH-2 cells was observed in all HIV-1-positive plasma samples tested ranging
from 19% (G022) to 40% (G025) with a mean value of 32% (±6%, n=6) in ART-naïve
patients (Fig. 5A), and from 17% (R02) to 29% (R06) with a mean value of 25% (±7%, n=9)
in patients on ART (Fig. 5A). HIV-1-positive plasma alone or plasma plus heat-inactivated
complement showed a background spontaneous cytolysis of 3.4% and 3.0%, respectively
(Fig. 5A, 5C). Plasma from uninfected individuals showed a background cytolysis of 5.3%,
which is not significantly different from background seen with plasma alone or plasma plus
heat-inactivated complement (Fig. 5A, 5C). The plasma samples did not have significant
ADCML of HIV-1-negative A3.01 cells treated with RMD (Fig. 5B, 5C). These results
indicate that the CD59 blocker (BRIC229) is able to specifically allow anti-HIV-1 Abs
naturally present in infected individuals to trigger ADCML of latently infected T cells upon
provirus activation.
ADCML of latently HIV-1-infected primary resting CD4+ T cells by anti-HIV-1 Env pAbs
Primary CD4+ T cell models of HIV-1 latency closely recapitulate the biology of HIV-1
latency in vivo. These models have facilitated research on the mechanisms of HIV-1 latency
and have also served as a platform for studying candidate compounds that have a potential to
purge the latent reservoirs. We used the spinoculation-infection approach to establish HIV-1
latency in primary resting CD4+ T cells without activation of these cells as previously
reported (48). As shown in Fig. 6A, integrated HIV-1 DNA was measured by the nested
Alu-qPCR in primary resting CD4+ T cells 3 days after spinoculation-infection, while p24 in
cell culture supernatants were at levels below detectable as determined by p24 ELISA (Data
not shown). These results were consistent with those of other studies and indicate
establishment of HIV-1 latency in primary resting CD4+ T cells (48, 49, 64).
To determine the frequency of primary resting CD4+ T cells that contained integrated viral
DNA, we stimulated these cells 3 days after spinoculation-infection with RMD (3 nM) or
anti-CD3/anti-CD28 beads for 24 h. Stimulated cells were subjected to intracellular staining
with anti-p24Gag mAb (KC57). As shown in Fig. 6B, 5.0% of spinoculated-infected primary
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resting CD4+ T cells were viral Gagpositive in response to stimulation with anti-CD3/anti-
CD28 beads, whereas unstimulated cells produced minimal or no Gag (Fig. 6B). RMD
induced Gag production in 3.1 % of latently infected primary resting CD4+ T cells, which is
62% of maximal activation (anti-CD3/anti-CD28 beads). As a control, RMD induced Gag
production in more than 65% of ACH-2 cells (Fig. 6B, 6C). Thus, approximately 5% of
latently infected primary resting CD4+ T cells contain replication-competent provirus (Fig.
6C), which is in agreement with that previously reported (48).
Next, we tested whether abrogation of CD59 function would render provirus-activated
latently infected primary resting CD4+ T cells sensitive to ADCML. Spinoculated-infected
primary resting CD4+ T cells were stimulated with RMD (3 nM), followed by incubation
with BRIC229 (20 μg/ml) plus rabbit anti-Env pAbs at various concentrations and
complement. Cytolysis of these primary cells was measured by reduction of integrated viral
DNA. Cells in all ADCML experimental conditions were treated with DNase enzymes to
remove DNA released from lysed cells, and then subjected to DNA extraction for
quantitating integrated HIV-1 DNA using the nested Alu-Gag qPCR. The level of integrated
HIV-1 DNA detected in the ADCML control (anti-gp120/gp160 pAbs only) was used to
calculate relative levels of integrated HIV-1 DNA detected in ADCML experimental
conditions (anti-gp120/gp160 pAbs plus competent complement or heat-inactivated
complement). As shown in Fig. 6D, the level of integrated HIV-1 DNA detected in the
ADCML experimental condition (RMD + BRIC229 + anti-HIV-1 Env + complement) was
significantly reduced when compared with control conditions including RMD + BRIC229 +
anti-HIV-1 Env + heat-inactivated complement, RMD + BRIC229 + irrelevant Abs or
medium only + complement. Thus, blockage of hCD59 with BRIC229 markedly increased
cytolysis of latently infected primary resting CD4+ T cells after provirus activation by RMD.
The lysis resulted from specific cell killing by anti-HIV-1 Env pAb-mediated ADCML
because the lysis did not occur in the controls described above.
Discussion
Efforts to eradicate long-lived latently HIV-1-infected cells have focused on activation of
the proviruses in these cells. This is known as a “shock and kill” approach. It is presumed
that these latently infected cells will be killed after provirus activation by virus-mediated
CPEs, host immune responses or both. This approach has to be implemented in HIV-1-
infected patients on ART to prevent new rounds of infections by virus released from the
stimulated cells. A recent study has demonstrated that a single 400 mg oral dose of SAHA
disrupts virus latency in HIV-1-infected patients in whom viremia has been fully suppressed
by ART (26). This report provides proof-of-concept for use of provirus stimulants,
particularly HDACi, as a therapeutic class of reagents with a tolerable safety profile while
they force activation of HIV-1 proviruses in vivo. However, the use of SAHA in
combination with suppressive ART in this study did not significantly reduce the number of
latently infected resting CD4+ T cells, suggesting that either viral CPEs or the immune
response is not sufficient to clear HIV-1 reservoirs and that additional interventions are
required. HIV-1 is cytopathic in vitro in cultured cells, but the viral replication elicits little
CPEs in vivo (15–19). In addition, viral CPEs may be attenuated by ART due to suppression
of production of infectious, mature virions. We found that provirus stimulants including
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prostratin, RMD and SAHA activated proviruses in the latently HIV-1-infected T cell line
ACH-2 as virion production and viral protein expression on the cell surface were induced
(Fig. 1). We also noticed that SQV, a PI, attenuated the effects of provirus stimulants
including RMD, SAHA, and prostratin on virion production from latently infected cells, as
virions determined by p24 ELISA in the supernatant of provirus-activated ACH-2 cells
decreased dramatically (Fig. 2). As a typical ART regimen combines three antiretroviral
drugs, most often including PIs and RTs, these drugs should be carefully selected when used
in combination with provirus stimulants. RTs and other PIs such as ATV and DRV should
be given priority as they do not affect neither cells expressing viral proteins nor viral
production (Fig. 2). In the SAHA clinical trial (26), PI-containing ART regimen(s) might
have been used (personal communication with Dr. Margolis D. at UNC), although the exact
ART regimens were not tracked. However, it is unlikely that the efficacy of the SAHA trial
was substantially influenced by PI-attenuated CPEs, as CPEs do not play a significant role in
the killing of HIV-1-infected cells in vivo (15–19).
HIV-1-infected patients are well known to mount a vigorous and sustained Ab response at
all stages of viral infection (32–39). This response is also well known to have a limited
effect on controlling virus proliferation or on protecting the patients from developing AIDS
(38, 40–42). Recent studies have indicated that resistance of HIV-1 virions or infected cells
to ADCML is dependent on RCA molecules including CD46, CD55 and CD59 (27–31).
CD59 controls formation of the membrane attack complex (MAC) at the terminal stage of
the complement activation cascades via all three activation pathways, whereas CD55 only
prevents formation of the C3 and C5 convertases (65–67) and CD46 only acts as a cofactor
for the cleavage of cell-bound C4b and C3b by the serum protease factor (68). Thus, CD59
plays the most critical role in restricting ADCML of HIV-1 virions and infected cells.
Blockage of CD59 strongly enhances ADCML of HIV-1 virions, whereas blockage of CD46
or CD55 has a significantly weaker effect (28). We therefore focused on the abrogation of
CD59 function to enhance ADCML of latently HIV-1-infected cells upon provirus
activation. We showed that Env and CD59 were strongly colocalized in lipid rafts on the
surface of provirus-activated cells, suggesting that Env may directly interact with RCA
molecules on the cell surface (Fig. 3). ACH-2 cells post-activation of provirus became
sensitive to ADCML in the presence of an hCD59 blocker plus anti-HIV-1 Env Abs (Fig. 4)
or plasma from HIV-1-infected patients (Fig. 5). Abrogation of CD59 function can restore
the functions of Abs in the plasma from both groups of patients who are on ART or ART-
naïve to trigger ADCML of provirus-activated latently infected cells (Fig. 5). It seems that
Abs present in ART-naïve patients have stronger cytotoxic activities than that in patients on
ART (Fig. 5C). However, a larger sample size is necessary to analyze the statistical
significance. The ADCML of provirus-activated cells resulted from specific cell killing by
anti-HIV-1 Abs because ADCML did not occur using irrelevant Abs, HIV-1-negative
plasma or inactivated complement (Fig. 4, Fig. 5). Therefore, a combination of provirus
stimulants with RCA blockers represents a novel approach for purging HIV-1 latently
infected cells. The remaining issues to be addressed include (1) whether ADCML efficacy is
correlated to the titer, neutralization activity and affinity of anti-HIV-1 Abs naturally present
in infected individuals, and (2) whether simultaneous abrogation of CD46, CD55 and CD59
can further enhance ADCML of latently HIV-1-infected cells upon provirus activation.
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Primary CD4+ T cell models of HIV-1 latency closely recapitulate the biology of HIV-1
latency in vivo. Several primary cell models of HIV-1 latency have been established (7, 69).
These models have facilitated research on the mechanisms of HIV-1 latency and have also
served as a platform for studying candidate compounds that have a potential to purge the
latent reservoirs. Spinoculation of HIV-1 with primary CD4+ T cells is a model that
establishes HIV-1 latency without activation of CD4+ T cells(7, 48, 70). Spinoculation-
infection has the ability to establish latency in all populations of primary CD4+ T cells
including naïve and memory CD4+ T cells, whereas other models predominantly establish
HIV-1 latency in memory CD4+ T cells. This model is also able to achieve a high
percentage of cells harboring replication-competent provirus (48), thereby providing large
numbers of latently-infected primary cells that can be used to study HIV-1 latency and the
effects of agents on provirus activation. We used the spinoculation-infection approach to
establish HIV-1 latency in primary resting CD4+ T cells without activation of these cells as
previously reported (48) (Fig. 6A). Approximately 5% of latently infected primary resting
CD4+ T cells contain replication-competent provirus, which is in agreement with that
previously reported (48) (Fig. 6B, 6C). RMD effectively induced Gag production from
latently infected primary resting CD4+ T cells and ACH-2 cells (Fig. 6B, 6C). Blockage of
hCD59 with BRIC229 markedly increased cytolysis of latently infected primary resting
CD4+ T cells after provirus activation by RMD (Fig. 6D). Thus, disarming RCA-protective
shield allows anti-HIV-1 Env Abs to specifically trigger ADCML of latently infected
primary cells and cell lines after provirus reactivation.
Because CD59 is widely expressed on almost all human cells and protects self-cells from
damage caused by complement activation, potential side effects may be the main obstacle in
clinical application of CD59 blockers. However, accumulating data suggest that short-term
or transient abrogation of CD59 may be feasible and tolerable to HIV-1 patients: (1)
intravenous (i.v.) injection of anti-rat CD59 Ab F(ab′)2 fragments completely inhibits rat
CD59 function in vivo without causing any side effects in rats (71), (2) CD59 knockout mice
do not develop severe illnesses (72), and (3) in vivo use of Abs against CD55 and CD59
increases the antitumor activity of Rituximab (anti-CD20 Ab) against lymphomas without
causing hemolysis in a murine model (73). In addition, paroxysmal nocturnal
hemoglobinuria (PNH) is a disease in humans due to deficiency of
glycosylphosphatidylinositol-anchored proteins (GPI-APs) including CD59 (74–79).
Patients with PNH usually have hemolytic anemia, but survive (74–79). Furthermore, we
and others have demonstrated that the use of CD59 inhibitors in vitro to block CD59 does
not cause nonspecific cytolytic effect of cell lines, human RBCs or PBMCs in the presence
of sera/plasma from HIV-1-infected patients (28, 80). Finally, CD59 blockers are expected
to be used short-term, not lifelong, thus making them easier to tolerate in HIV-1 patients.
In conclusion, HDACi (RMD and SAHA) and prostratin activate proviruses in the latently
infected cells, resulting in virion production and viral protein expression on the cell surface.
RMD was the most attractive provirus stimulant as it effectively activated proviruses at
nanomolar concentrations that can be achieved clinically. Abrogation of CD59 function in
conjunction with anti-HIV-1 Abs, either exogenous like the anti-HIV-1 Env Abs or
endogenous such as those in plasma from HIV-1-infected patients, efficiently triggers
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ADCML of provirus-activated ACH-2 cells in the presence or absence of antiretroviral
drugs. Both ART-naïve patients and patients on ART have virus-specific Abs that are
capable of mediating cytotoxicity of provirus-activated cell. This approach also effectively
enhances ADCML of latently HIV-1-infected primary CD4+ T cells. Therefore, a
combination of provirus stimulants with RCA blockers helps restore function of naturally
occurring Abs present in HIV-1-infected patients to trigger ADCML of latently infected
cells, thereby representing a potentially novel approach to eliminate HIV-1.
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RCA regulators of complement activation
ADCML antibody-dependent complement-mediated lysis
HDACi histone deacetylase inhibitor
RMD romidepsin
SAHA suberoylanilide hydroxamic acid
ART antiretroviral therapy
CPE cytopathic effect
VPA valproic acid
pAb polyclonal antibody
CTB cholera toxin subunit B
ICS intracellular staining
RT reverse transcriptase
PI protease inhibitor
FTC emtricitabine
SQV saquinavir
ATV atazanavir
DRV darunavir
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Fig. 1. HIV-1 protein expression on the surface of latently-infected T cells upon provirus
activation
J-Lat GFP Clone A72 cells and ACH-2 cells were incubated with RMD, SAHA, and
prostratin at various concentrations as indicated. DMSO and PMA (10 ng/ml) plus
ionomycin (1 μg/ml) were used as negative and positive stimulation controls, respectively.
Stimulated J-Lat GFP Clone A72 cells were directly subjected to fluorescence microscopy
analysis to determine provirus activation (GFP-positive). Stimulated ACH-2 cells were
subjected to immunostaining with an anti-gp120 mAb (2G12) to determine expression of
HIV-1 Env on the cell surface, and supernatant was subjected to p24Gag ELISA to determine
levels of HIV-1 production in response to various provirus stimulants. A) A representative
experiment of fluorescence microscopy analysis shows provirus activation in J-Lat GFP
Clone A72 cells. B) Representative experiments of FACS analysis show the results of
ACH-2 cells expressing gp120 on the cell surface 24 h post-stimulation with RMD (3 nM),
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SAHA (0.4 μM), and prostratin (1 μM). C) Pooled data from three separate experiments of
FACS analysis show the % of gp120-positive ACH-2 cells 24 - 72 h post-stimulation with
RMD, SAHA, or prostratin at various concentrations as indicated. D) HIV-1 p24 levels in
the supernatants from ACH-2 cells 24 h poststimulation with RMD (3 nM), SAHA (0.4
μM), or prostratin (1 μM). PMA, PMA (10 ng/mL) plus ionomycin (1 μg/mL). All
experiments were repeated at least three times.
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Fig. 2. Effects of antiretroviral drugs on virus production and viral protein expression
ACH-2 cells were untreated or treated with RMD (3 nM), SAHA (0.8 μM), prostratin (1
μM), DMSO, or PMA (10 ng/ml) plus ionomycin (1 μg/ml) in the presence or absence of a
RT inhibitor such as FTC, or a PI such as SQV, ART, or DRV at various concentrations as
indicated to study possible effects of antiretroviral drugs on provirus activation. A) and B)
Supernatants and cells were collected 24 h posttreatment for p24 ELISA and FACS analysis
to determine viral titer in the culture supernatants and % of gp120-positive cells,
respectively. C) Cellular lysates were subjected to Western blot to analyze expression of
Gag precursor and matured molecules. The data shows that SQV, but not other antiretroviral
drugs, markedly inhibits cleavage of precursor Gag into mature capsid p24, resulting in little
or no processed p24. The data represent the results from at least three independent
experiments. FTC, emtricitabine; SQV, saquinavir; ATV, atazanavir; DRV, darunavir; Med,
medium only; P, prostratin.
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Fig. 3. Colocalization of Env and hCD59 in lipid rafts on the surface of ACH-2 cells upon
provirus activation
ACH-2 cells were untreated or treated with RMD (3 nM), SAHA (0.8 μM), prostratin (1
μM), DMSO, or PMA (10 ng/ml) plus ionomycin (1 μg/ml) for 24 h, and then subjected to
confocal microscopy analysis of viral protein expression on the cell surface. White color in
merged panel indicates the colocalization of HIV-1 Env (red) with lipid rafts (green) and
CD59 (magenta) on the surface of provirus-activated ACH-2 cells. Cellular DNA content
and nuclei were stained with DAPI (blue). Scale bars represent 5 μm. The data represent the
results from at least three independent experiments. CTB, cholera toxin subunit B as a
marker for lipid rafts; gp120, surface staining with 2G12, a mAb against HIV-1 gp120.
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Fig. 4. Anti-Env Abs triggered ADCML of ACH-2 cells upon provirus activation
A) A hemolysis assay was conducted to determine the most efficient blocking concentration
of BRIC229 in abrogation of hCD59 function. BRIC229 at 20 μg/ml completely abrogated
hCD59 function as ADCML of human RBCs reached almost 100% (line with solid black
circles), whereas RBCs resisted to ADCML in the absence of BRIC229 (dotted line with
open circles). B) Anti-Env pAbs triggered ADCML of provirus-activated ACH-2 cells in a
dose-dependent manner (line with solid black diamonds). Neither heat-inactivated
complement (gray line with solid gray circles) nor irrelevant rabbit IgG pAbs (black line
with open circles) triggered cytolysis of ACH-2 cells. C) A3.01 cells that are ACH-2
parental cells prior to HIV-1-infection were resistant ADCML. The cytolysis did not occur
in any of the conditions mentioned above. D) Comparisons of ADCML efficacy of provirus-
activated ACH-2 cells in the absence (Med condition) or presence of antiretroviral drugs
(SQV, 5 μM; ATV, 8 nM; DRV, 9 nM; FTC, 5 μM). The data represent the results from at
least three independent experiments. Black line with solid black diamonds: anti-Env pAbs
plus complement; gray line with solid gray circles: anti-Env pAbs plus heat-inactivated
complement; black line with open circles: irrelevant rabbit IgG pAbs plus complement. C,
complement; iC, heat-inactivated complement.
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Fig. 5. Specific lysis of provirus-activated ACH-2 cells by anti-HIV-1 Abs present in plasma of
infected patients
Plasma samples from 15 chronically HIV-1-infected patients including 6 patients on virally-
suppressive ART and 9 ART-naïve patients were tested for their activity in triggering
ADCML of provirus-activated ACH-2 cells. Plasma samples from 5 uninfected individuals
were included as controls. A) Cytolysis of provirus-activated ACH-2 cells by plasma
samples from HIV-1-infected patients on ART or ART-naïve or plasma from uninfected
individuals. B) A3.01 cells were resistant to ADCML by plasma samples from HIV-1-
infected patients on ART or ART-naïve or from uninfected individuals. All plasma samples
were heat-inactivated at 56°C for 30 min to destroy complement prior to performing the
ADCML, and the final dilution of plasma was 1:10. C) Pooled data of cytolysis by plasma
samples from HIV-1-infected patients on ART or ART-naïve or from uninfected
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individuals. The experiments were repeated twice for each test. The results are represented
by mean ± SD. Black bars (negative controls), ACH-2 cells treated with BRIC229 (20
μg/ml) + heat-inactivated plasma as a source of anti-HIV-1 Abs, but no complement was
added; Open bars (experimental ADCML), ACH-2 cells treated with BRIC229 (20 μg/ml) +
heat-inactivated plasma as a source of anti-HIV-1 Abs + complement; Gray bars
(complement controls), cells treated with BRIC229 (20 μg/ml) + heat-inactivated plasma as
a source of anti-HIV-1 Abs + heat-inactivated complement. Plasma, only plasma, no
complement; Plasma + C, plasma plus complement; Plasma + iC: plasma plus heat-
inactivated complement. Statistical significance (**p < 0.01 versus no complement or heat-
inactivated complement) is indicated by asterisks, while ns indicates no statistical difference.
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Fig. 6. Anti-Env Abs triggered ADCML of latently HIV-1-infected primary resting CD4+ T cells
The spinoculation-infection approach was used to establish HIV-1 latency in primary resting
CD4+ T cells without activation of these cells as previously reported (48). A) Integrated
HIV-1 DNA was measured from DNA samples prepared from primary resting CD4+ T cells
3 day after the spinoculation-infection using the nested Alu-Gag qPCR as previously
described (49). DNA samples prepared from unstimulated ACH-2 cells and A3.01 cells
were subjected to the nested Alu-Gag qPCR to serve as positive and negative controls of
HIV-1 integration, respectively. The data are representative of three independent
experiments. B) A fraction of latently infected primary resting CD4+ T cells contains
replication-competent provirus. In each FACS plot, the percentage of p24-positive primary
CD4+ T cells or ACH-2 cells in response to RMD stimulation in the boxed region is shown.
Anti-CD3/anti-CD28 beads and PMA (10 ng/ml) plus ionomycin (1 μg/ml) were used as
positive stimulants to stimulate primary CD4+ T cells and ACH-2 cells, respectively. The
experiments were performed in the presence of SQV (1.25 μM) to prevent spreading
infection as previously described (48). Uninfected resting primary CD4+ T cells and A3.01
cells were treated as the same as the latently infected cells. They were used as controls for
background staining with the anti-Gag mAb (KC57). Staining with an isotype-matched
control mAb was also used to obtain staining background. C) Pooled data show the
percentage of p24-positive cells as determined by intracellular p24 staining from latently-
infected primary cells from 3 donors (n=3) or from ACH-2 cells in response to RMD
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stimulation for 3 days. D) Anti-Env pAbs triggered ADCML of provirus-activated primary
CD4+ T cells (open bars). Neither heat-inactivated complement (gray bars) nor medium
alone or irrelevant rabbit IgG pAbs (black bars) triggered cytolysis of these cells. The results
are represented by mean ± SD of ADCML of three blood donors. Open bars, cells treated
with BRIC229 (20 μg/ml) + anti-HIV-1 pAbs + complement; Gray bars (complement
controls), cells treated with BRIC229 (20 μg/ml) + anti-HIV-1 pAbs + heat-inactivated
complement; Black bars, cells treated with BRIC229 (20 μg/ml) + anti-HIV-1 pAbs +
medium. Statistical significance (**p < 0.01 versus no complement or heat-inactivated
complement) is indicated by asterisks, while ns indicates no statistical difference.
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